TriNetX, 125 Cambridgepark Drive, Suite 500, Cambridge, MA 02140, USA.
Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Mult Scler Relat Disord. 2023 Nov;79:104943. doi: 10.1016/j.msard.2023.104943. Epub 2023 Aug 23.
The use and potential benefit of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in people living with multiple sclerosis (pwMS) remains poorly studied. The objective of this study is to describe the therapeutic use of anti-SARS-CoV-2 mAbs among pwMS.
This retrospective cohort study used electronic medical records data from the TriNetX Dataworks USA Network and included adult pwMS, diagnosed with COVID-19, who received anti-SARS-CoV-2 mAbs in the outpatient setting between November 2020 and April 2022. We analyzed COVID-19 severity at anti-SARS-CoV-2 mAb initiation and up to 30 days, stratified by before/after emergence of Omicron variant and by disease-modifying therapy (DMT).
The study included 434 pwMS treated with anti-SARS-CoV-2 mAbs for mild-to-moderate COVID-19, including 270 patients before and 174 after Omicron emergence. Most pwMS were female (80.2%), mean age (SD) was 51.5 (12.5) years. Two-hundred-and-five patients were on DMTs, 51% of whom received anti-CD20s. One patient with moderate COVID-19 was hospitalized whilst receiving glatiramer acetate. No patients required intensive care and there were no deaths. COVID-19 outcomes were comparable following anti-SARS-CoV-2 mAb therapy in patients receiving different DMTs.
Anti-SARS-CoV-2 mAb treatment for pwMS with mild-to-moderate COVID-19 may reduce the risk of COVID-19-related hospitalization and death.
在多发性硬化症（pwMS）患者中，使用抗严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）单克隆抗体（mAbs）治疗轻度至中度 2019 年冠状病毒病（COVID-19）的作用和潜在益处仍研究甚少。本研究的目的是描述 pwMS 中抗 SARS-CoV-2 mAbs 的治疗用途。
这是一项回顾性队列研究，使用了 TriNetX Dataworks USA 网络的电子病历数据，纳入了在 2020 年 11 月至 2022 年 4 月期间在门诊接受过抗 SARS-CoV-2 mAbs 治疗的、被诊断为 COVID-19 的成年 pwMS 患者。我们分析了抗 SARS-CoV-2 mAb 起始时以及 30 天内 COVID-19 的严重程度，按奥密克戎变异出现前后以及疾病修正治疗（DMT）进行分层。
该研究纳入了 434 例接受抗 SARS-CoV-2 mAbs 治疗轻度至中度 COVID-19 的 pwMS 患者，其中奥密克戎出现前 270 例，奥密克戎出现后 174 例。大多数 pwMS 为女性（80.2%），平均年龄（标准差）为 51.5（12.5）岁。205 例患者正在接受 DMT，其中 51%接受了抗 CD20s。1 例中等程度 COVID-19 患者在接受醋酸格拉替雷治疗时住院。没有患者需要重症监护，也没有死亡。接受不同 DMT 的患者接受抗 SARS-CoV-2 mAb 治疗后的 COVID-19 结局相似。
抗 SARS-CoV-2 mAb 治疗 pwMS 轻度至中度 COVID-19 可能降低 COVID-19 相关住院和死亡的风险。
